Heart:食盐替代品对临床结局的影响

2022-08-12 MedSci原创 MedSci原创

食盐替代品对血压的有益效应在不同地域和人群中是一致的。血压介导对临床结局的保护作用值得在世界各国进行推广。

食盐代谢物和卒中研究(SSaSS)最近报道了一种通过血压调节介导对心血管结局和死亡具有益处的富钾盐代谢物。近日,心脏病领域权威杂志Heart上发表了一篇研究文章,该研究评估了盐替代品对一系列结局的影响,以量化研究结果的一致性,并了解SSaSS结果可能的推广价值。

研究人员检索了PubMed、Embase和Cochrane Library,检索截止时间至2021年8月31日。研究人员纳入了报告食盐替代品对血压或临床结局影响的平行组、阶梯式或聚类随机对照试验,并使用Meta分析和回归来定义跨试验、地理和患者群体结果的一致性。

该研究共纳入了21项试验和31949名参与者,其中19项研究报告了其对血压的影响,5项报告了对临床结局的影响。收缩压(SBP)下降为−4.61mmHg(95%CI为−6.07~−3.14),舒张压(DBP)下降为−1.61mmHg(95%CI为−2.42~−0.79)。根据年龄、性别、高血压病史、身重指数、基线血压、基线24小时尿钠和基线24小时尿钾,各个地理区域和人群亚组的血压降低似乎是一致的(所有同质性P>0.05)。回归分析显示,食盐替代物中氯化钠比例每降低10%,收缩压就会降低−1.53mmHg(95%CI为−3.02~−0.03,p=0.045),舒张压降低−0.95mmHg(95%CI为−1.78~−0.12,p=0.025)。食盐代用品对总死亡率(风险比(RR)为0.89,95%CI为0.85~0.94)、心血管死亡率(RR为0.87,95%CI为0.81~0.94)和心血管事件(RR为0.89,95%CI为0.85~0.94)具有明显的保护作用。

由此可见,食盐替代品对血压的有益效应在不同地域和人群中是一致的。血压介导对临床结局的保护作用值得在世界各国进行推广。

原始出处:

Xuejun Yin.et al.Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis.heart.2022.https://heart.bmj.com/content/early/2022/07/21/heartjnl-2022-321332

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1843297, encodeId=7b97184329eb2, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 09 20:23:10 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357963, encodeId=d826135e96332, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423686, encodeId=4b55142368627, content=<a href='/topic/show?id=cfd51010566b' target=_blank style='color:#2F92EE;'>#食盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101056, encryptionId=cfd51010566b, topicName=食盐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1c53824481, createdName=lingqf, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563648, encodeId=f4d01563648d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1843297, encodeId=7b97184329eb2, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 09 20:23:10 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357963, encodeId=d826135e96332, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423686, encodeId=4b55142368627, content=<a href='/topic/show?id=cfd51010566b' target=_blank style='color:#2F92EE;'>#食盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101056, encryptionId=cfd51010566b, topicName=食盐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1c53824481, createdName=lingqf, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563648, encodeId=f4d01563648d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
    2022-08-13 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1843297, encodeId=7b97184329eb2, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 09 20:23:10 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357963, encodeId=d826135e96332, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423686, encodeId=4b55142368627, content=<a href='/topic/show?id=cfd51010566b' target=_blank style='color:#2F92EE;'>#食盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101056, encryptionId=cfd51010566b, topicName=食盐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1c53824481, createdName=lingqf, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563648, encodeId=f4d01563648d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
    2022-08-13 lingqf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1843297, encodeId=7b97184329eb2, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 09 20:23:10 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357963, encodeId=d826135e96332, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423686, encodeId=4b55142368627, content=<a href='/topic/show?id=cfd51010566b' target=_blank style='color:#2F92EE;'>#食盐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101056, encryptionId=cfd51010566b, topicName=食盐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1c53824481, createdName=lingqf, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563648, encodeId=f4d01563648d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Aug 13 09:23:10 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
    2022-08-13 slcumt

相关资讯

Crit Care:重症成人营养治疗与临床结局

热量摄入量主要根据ESPEN指南推荐的目标来提供,但蛋白质摄入量较低。在ICU住院5天以上的患者中,每日摄入中等热量和蛋白质与改善临床结局相关。

Stroke:卒中-心脏综合征:卒中后心脏并发症的发生率和临床结局

缺血性卒中后新发心血管并发症非常常见,主要不良心血管事件的5年预后明显较差。卒中及新诊断心血管并发症患者5年卒中复发发生率为50%。

Diabetes Care:COVID-19患者血糖控制与临床结局的关系

在美国一个大型、多中心的2型糖尿病和COVID-19感染患者队列中,住院风险随着糖化血红蛋白水平的升高而增加。死亡和有创通气的风险也增加了,但在不同的血糖控制水平下趋于稳定。

JAHA:花粉浓度的时间变化预测急性冠状动脉综合征的短期临床结局

花粉浓度增加与不同的ACS亚型无关,但与经皮冠状动脉介入治疗后的住院死亡率显著相关,强调了花粉暴露与临床结局之间的潜在生物学联系。

Haematologica:40年来,7+3诱导方案治疗AML的临床结局改善情况

7 + 3方案事实上也会随时间变化,两种药物的剂量均随时间变化,而多变量分析无法校正与研究/时期完全混淆的因素。